became immunocompromised a few months after the first booster.; throat cancer; This spontaneous case was reported by a pharmacist and describes the occurrence of IMMUNODEFICIENCY (became immunocompromised a few months after the first booster.) and THROAT CANCER (throat cancer) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Non-smoker.   On an unknown date, the patient received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form and first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced IMMUNODEFICIENCY (became immunocompromised a few months after the first booster.) (seriousness criterion medically significant) and THROAT CANCER (throat cancer) (seriousness criterion medically significant). At the time of the report, IMMUNODEFICIENCY (became immunocompromised a few months after the first booster.) and THROAT CANCER (throat cancer) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter considered THROAT CANCER (throat cancer) to be not related. No further causality assessment was provided for IMMUNODEFICIENCY (became immunocompromised a few months after the first booster.).    No concomitant medication was known by reporter.  It was reported that the patient received 2 primary doses and a first booster dose and became immunocompromised a few months after the first booster. Patient was diagnosed with throat cancer and was on chemotherapy.  Company comment-This spontaneous case concerns a female patient of unknown age, with no medical history reported, who experienced the unexpected serious (medically significant) events of Immunodeficiency and Throat cancer on unknown dates after the 3rd dose of mRNA-1273 vaccine. It was reported that patient received 2 primary doses and a first booster, was immunocompromised a few months after the first booster, was diagnosed with throat cancer and is on chemotherapy. Clinical course, lab reports and treatment details were not reported. The outcome of events was unknown. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events seriousness was assessed based on medical judgement.   Most recent FOLLOW-UP information incorporated above includes: On 27-Jun-2022: Follow up included: Patient details, medical history, new event, vaccine indication and reporter causality.; Sender's Comments: This spontaneous case concerns a female patient of unknown age, with no medical history reported, who experienced the unexpected serious (medically significant) events of Immunodeficiency and Throat cancer on unknown dates after the 3rd dose of mRNA-1273 vaccine. It was reported that patient received 2 primary doses and a first booster, was immunocompromised a few months after the first booster, was diagnosed with throat cancer and is on chemotherapy. Clinical course, lab reports and treatment details were not reported. The outcome of events was unknown. The benefit-risk relationship of mRNA-1273 is not affected by this report. Events seriousness was assessed based on medical judgement.